美迪紫檀素 | 32383-76-9

• 物质功能分类: 天然产物 - 酚类
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 中文名称: 美迪紫檀素
• 英文名称: medicarpin
• 英文别名: 9-methoxy-6α,11α-dihydro-6H-benzo[4,5]furo[3,2-c]chromen-3-ol；(6aR,11aR)-9-methoxy-6a,11a-dihydro-6H-[1]benzofuro[3,2-c]chromen-3-ol；(6aR,11aR)-9-methoxy-6a,11a-dihydro-6H-benzofuro[3,2-c]chromen-3-ol；(6aR,11aR)-3-hydroxy-9-methoxypterocarpan；7-hydroxy-4′-methoxypterocarpan；(6αR,11αR)-medicarpin
• CAS: 32383-76-9
• 化学式: C₁₆H₁₄O₄
• 分子量: 270.285
• InChiKey: NSRJSISNDPOJOP-BBRMVZONSA-N

物化性质

• 熔点：
  127.5-128.5°
• 比旋光度：
  D22 -226° (chloroform)
• 沸点：
  418.8±45.0 °C(Predicted)
• 密度：
  1.319±0.06 g/cm3(Predicted)
• 溶解度：
  溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  47.9
• 氢给体数：
  1
• 氢受体数：
  4

制备方法与用途

生物活性

Medicarpin 是一种从紫花苜蓿中分离出的类黄酮。研究显示，Medicarpin 通过调节 P-gp 介导的药物外流，诱导白血病 P388 细胞凋亡，并克服多药耐药性。

体外研究

在体外实验中，Medicarpin（90 µM；48 小时）能够触发敏感及多重耐药 P388 细胞的凋亡。表达 P-糖蛋白的 P388/DOX 细胞对 Medicarpin 并不表现出耐药性（IC50 ≈ 90 µM，适用于 P388 和 P388/DOX 细胞）。

反应信息

• 作为反应物：
  描述：

  美迪紫檀素 、 uridine-5'-diphosphoglucose 在 TcCGT₁-C-glycosyltransferase from Trolliuschinensisuridine in complex with uridine diphosphate 作用下， 以 aq. phosphate buffer 为溶剂， 反应 2.0h， 生成 美迪紫檀素葡萄糖苷
  参考文献：
  名称：

  中华金莲花混杂C-糖基转移酶的分子和结构表征。

  摘要：

  在本文中，探索了药用植物金莲花（Trollius chinensis）中新的C-糖基转移酶（CGT）TcCGT1的催化混杂性。TcCGT1可以有效和区域特异性地催化36种黄酮和其他类黄酮的8 C糖基化，还可以催化多种酚的O糖基化。TcCGT1与尿苷二磷酸酯复合的晶体结构以1.85Å的分辨率测定。分子对接揭示了TcCGT1催化机制的新模型，该模型由底物的自发去质子化引发。宽大的装订袋说明了基材的混杂性，并且基材的装订姿势决定了C或O糖基化活性。位点定向诱变在两个残基（I94E和G284K）切换Ç -到Ò -glycosylation。TcCGT1是第一个具有晶体结构的植物CGT，并且是第一个描述的黄酮8- C-糖基转移酶。这为设计有效的糖基化生物催化剂提供了基础。

  DOI：

  10.1002/anie.201905505
• 作为产物：
  描述：

  刺芒柄花素 生成 美迪紫檀素
  参考文献：
  名称：

  Catalytic specificity of pea O-methyltransferases suggests gene duplication for (+)-pisatin biosynthesis

  摘要：

  S-adenosyl-L-methionine: 2-hydroxyisoflavanone 4'-O-methyltransferase (HI4'OMT) methylates 2,7, 4'-trihydroxyisoflavanone to produce formononetin, an essential intermediate in the synthesis of isoflavonoids with methoxy or methylenedioxy groups at carbon 4' (isoflavone numbering). HI4'OMT is highly similar (83% amino acid identity) to (+)-6a-hydroxymaackiain 3-O-methyltransferase (HMM), which catalyzes the last step of (+)-pisatin biosynthesis in pea. Pea contains two linked copies of HMM with 96% amino acid identity. In this report, the catalytic activities of the licorice HI4'OMT protein and of extracts of Escherichia coli containing the pea HMM1 or HMM2 protein are compared on 2,7,4'-trihydroxyisoflavanone and enantiomers of 6a-hydroxymaackiain. All these enzymes produced radiolabelled 2,7-dihydroxy-4'-methoxyisoflavanone or (+)-pisatin from 2,7,4'-trihydroxyisoflavanone or (+)-6a-hydroxymaakiain when incubated with [methyl-C-14]-S-adenosyl-L-methionine. No product was detected when (-)-6a-hydroxymaackiain was used as the substrate. HIWOMT and HMMI showed efficiencies (relative V-max/K-m) for the methylation of 2,7,4'-trihydroxyisoflavanone 20 and 4 times higher than for the methylation of (+)-6a-hydroxymaackiain, respectively. In contrast, HMM2 had a higher V-max and lower K-m on (+)-6a-hydroxymaackiain, and had a 67-fold higher efficiency for the methylation of (+)-6a-hydroxymaackiain than that for 2,7,4'-trihydroxyisoflavanone. Among the 15 sites at which HMMI and HMM2 have different amino acid residues, 11 of the residues in HMM1 are the same as found in HI4'OMTs from three plant species. Modeling of the HMM proteins identified three or four putative active site residues responsible for their different substrate preferences. It is proposed that HMM I is the pea HIWOMT and that HMM2 evolved by the duplication of a gene encoding a general biosynthetic enzyme (HIWOMT). (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.phytochem.2006.09.010

文献信息

• Enzymatic <i>O</i> ‐Prenylation of Diverse Phenolic Compounds by a Permissive <i>O</i> ‐Prenyltransferase from the Medicinal Mushroom <i>Antrodia camphorata</i>
  作者：Junbin He、Zhimin Hu、Zeyuan Dong、Bin Li、Kuan Chen、Zhanpeng Shang、Meng Zhang、Xue Qiao、Min Ye

  DOI：10.1002/adsc.201901396

  日期：2020.2.6

  Prenylated compounds are pharmacologically attractive natural products that are widely distributed in nature. Prenyltransferases (PTs) could catalyze the transfer of prenyl moieties to aromatic acceptors and increase the structural diversity and biological activity of natural products. In this work, a permissive O‐prenyltransferase AcaPT was discovered from Antrodia camphorata, a precious medicinal

  烯丙基化的化合物是在自然界中广泛分布的具有药理吸引力的天然产物。异戊二烯基转移酶（PTs）可以催化异戊二烯基团向芳族受体的转移，并增加天然产物的结构多样性和生物活性。在这项工作中，从台湾珍贵的香菇樟芝中发现了一种允许的邻戊二烯基转移酶AcaPT 。AcaPT对结构多样的药物样酚类化合物（包括Antrodins，类黄酮和香豆素）表现出强大的O-异戊二烯化能力。通过放大酶促合成，总共获得了23种O-异戊烯化产品。AcaPT可用作合成O的有效生物催化剂用于药物开发的异戊二烯基衍生物。
• [EN] POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À DES EXCIPIENTS POLYMÉRIQUES HYPERBRANCHÉS
  申请人：ASCENDIS PHARMA AS

  公开号：WO2013024048A1

  公开（公告）日：2013-02-21

  The present invention relates to water-soluble carrier-linked prodrugs of formula (I),wherein POL is a polymeric moiety,each Hyp is independently a hyperbranched moiety,each moiety SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, m is 0 or 1, each n is independently an integer from 2 to 200 and each x is independently 0 or 1. It further relates to pharmaceutical compositions comprising said water- soluble carrier-linked prodrugs and methods of treatment.

  本发明涉及水溶性载体连接的前药，其化学式为（I），其中POL是聚合物基团，每个Hyp是独立的超支化基团，每个基团SP是独立的间隔基团，每个L是独立的可逆前药连接基团，m为0或1，每个n是独立的整数，范围从2到200，每个x是独立的0或1。此外，还涉及包含所述水溶性载体连接的前药的药物组合物和治疗方法。
• [EN] HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À DES EXCIPIENTS HYDROSOLUBLES DE FORTE CHARGE
  申请人：ASCENDIS PHARMA AS

  公开号：WO2013024047A1

  公开（公告）日：2013-02-21

  The present invention relates to water-soluble carrier-linked prodrugs of formula (I), wherein B, A and Hyp form the carrier, B is a branching core, each A is independently a poly(ethylene glycol)-based polymeric chain, each Hyp is independently a branched moiety, each SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, each D is independendly a biologically active moiety, each x is independently 0 or 1, each m is independently an integer of from 2 to 64, n is an integer from 3 to 32; or the pharmaceutically acceptable salt thereof. It further relates to pharmaceutical compositions comprising said water-soluble carrier-linked prodrugs, their use asmedicament or diagnostic, and methods of treatment.

  本发明涉及水溶性载体连接的前药，其化学式为(I)，其中B、A和Hyp形成载体，B是一个分支核心，每个A独立地是一条聚乙二醇基聚合链，每个Hyp独立地是一个分支基团，每个SP独立地是一个间隔基团，每个L独立地是一个可逆前药连接基团，每个D独立地是一个生物活性基团，每个x独立地为0或1，每个m独立地是从2到64的整数，n是从3到32的整数；或其药学上可接受的盐。进一步涉及包括所述水溶性载体连接的前药的药物组合物，其用作药物或诊断，以及治疗方法。
• [EN] PROTEIN CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À UN EXCIPIENT PROTÉIQUE
  申请人：ASCENDIS PHARMA AS

  公开号：WO2013024049A1

  公开（公告）日：2013-02-21

  The present invention relates to water-soluble protein carrier- linked prodrugs wherein the protein carrier comprises an amino acid sequence consisting of at least 100 amino acid residues forming random coil conformation and comprising alanine, serine and proline residues. It further relates to pharmaceutical compositions comprising said water-soluble protein carrier- linked prodrugs, their use as a medicament as well as methods of treatment and administration.

  本发明涉及水溶性蛋白载体连接的前药，其中蛋白载体包括至少100个氨基酸残基组成的氨基酸序列，形成随机卷曲构象，包括丙氨酸、丝氨酸和脯氨酸残基。还涉及包含上述水溶性蛋白载体连接的前药的药物组合物，它们作为药物的用途，以及治疗和管理的方法。
• [EN] HYDROGEL-LINKED PRODRUGS RELEASING MODIFIED DRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À UN HYDROGEL LIBÉRANT DES MÉDICAMENTS MODIFIÉS
  申请人：ASCENDIS PHARMA AS

  公开号：WO2014173759A1

  公开（公告）日：2014-10-30

  The present invention relates to a process for the preparation of a hydrogel-linked prodrug releasing a tag moiety-bio logically active moiety conjugate, to a hydrogel-linked prodrug releasing a tag moiety-bio logically active moiety conjugate obtainable by such process, to pharmaceutical compositions comprising said prodrug and their use as a medicament.

  本发明涉及一种制备水凝胶连接的前药释放标签基团-生物活性基团结合物的方法，以及通过该方法获得的水凝胶连接的前药释放标签基团-生物活性基团结合物，还涉及包含该前药的药物组合物及其作为药物的用途。